• Je něco špatně v tomto záznamu ?

Human multipotent mesenchymal stem cells improve healing after collagenase tendon injury in the rat

L. Machova Urdzikova, R. Sedlacek, T. Suchy, T. Amemori, J. Ruzicka, P. Lesny, V. Havlas, E. Sykova, P. Jendelova,

. 2014 ; 13 (-) : 42.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074240

BACKGROUND: Mesenchymal stromal cells attract much interest in tissue regeneration because of their capacity to differentiate into mesodermal origin cells, their paracrine properties and their possible use in autologous transplantations. The aim of this study was to investigate the safety and reparative potential of implanted human mesenchymal stromal cells (hMSCs), prepared under Good Manufacturing Practice (GMP) conditions utilizing human mixed platelet lysate as a culture supplement, in a collagenase Achilles tendon injury model in rats. METHODS: Eighty-one rats with collagenase-induced injury were divided into two groups. The first group received human mesenchymal stromal cells injected into the site of injury 3 days after lesion induction, while the second group received saline. Biomechanical testing, morphometry and semiquantitative immunohistochemistry of collagens I, II and III, versican and aggrecan, neovascularization, and hMSC survival were performed 2, 4, and 6 weeks after injury. RESULTS: Human mesenchymal stromal cell-treated rats had a significantly better extracellular matrix structure and a larger amount of collagen I and collagen III. Neovascularization was also increased in hMSC-treated rats 2 and 4 weeks after tendon injury. MTCO2 (Cytochrome c oxidase subunit II) positivity confirmed the presence of hMSCs 2, 4 and 6 weeks after transplantation. Collagen II deposits and alizarin red staining for bone were found in 6 hMSC- and 2 saline-treated tendons 6 weeks after injury. The intensity of anti-versican and anti-aggrecan staining did not differ between the groups. CONCLUSIONS: hMSCs can support tendon healing through better vascularization as well as through larger deposits and better organization of the extracellular matrix. The treatment procedure was found to be safe; however, cartilage and bone formation at the implantation site should be taken into account when planning subsequent in vivo and clinical trials on tendinopathy as an expected adverse event.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074240
003      
CZ-PrNML
005      
20141007111436.0
007      
ta
008      
141006s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1475-925X-13-42 $2 doi
035    __
$a (PubMed)24712305
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Machova Urdzikova, Lucia $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic. urdzikl@saske.sk.
245    10
$a Human multipotent mesenchymal stem cells improve healing after collagenase tendon injury in the rat / $c L. Machova Urdzikova, R. Sedlacek, T. Suchy, T. Amemori, J. Ruzicka, P. Lesny, V. Havlas, E. Sykova, P. Jendelova,
520    9_
$a BACKGROUND: Mesenchymal stromal cells attract much interest in tissue regeneration because of their capacity to differentiate into mesodermal origin cells, their paracrine properties and their possible use in autologous transplantations. The aim of this study was to investigate the safety and reparative potential of implanted human mesenchymal stromal cells (hMSCs), prepared under Good Manufacturing Practice (GMP) conditions utilizing human mixed platelet lysate as a culture supplement, in a collagenase Achilles tendon injury model in rats. METHODS: Eighty-one rats with collagenase-induced injury were divided into two groups. The first group received human mesenchymal stromal cells injected into the site of injury 3 days after lesion induction, while the second group received saline. Biomechanical testing, morphometry and semiquantitative immunohistochemistry of collagens I, II and III, versican and aggrecan, neovascularization, and hMSC survival were performed 2, 4, and 6 weeks after injury. RESULTS: Human mesenchymal stromal cell-treated rats had a significantly better extracellular matrix structure and a larger amount of collagen I and collagen III. Neovascularization was also increased in hMSC-treated rats 2 and 4 weeks after tendon injury. MTCO2 (Cytochrome c oxidase subunit II) positivity confirmed the presence of hMSCs 2, 4 and 6 weeks after transplantation. Collagen II deposits and alizarin red staining for bone were found in 6 hMSC- and 2 saline-treated tendons 6 weeks after injury. The intensity of anti-versican and anti-aggrecan staining did not differ between the groups. CONCLUSIONS: hMSCs can support tendon healing through better vascularization as well as through larger deposits and better organization of the extracellular matrix. The treatment procedure was found to be safe; however, cartilage and bone formation at the implantation site should be taken into account when planning subsequent in vivo and clinical trials on tendinopathy as an expected adverse event.
650    _2
$a Achillova šlacha $x účinky léků $x zranění $7 D000125
650    _2
$a zvířata $7 D000818
650    _2
$a biomechanika $7 D001696
650    _2
$a karcinogeneze $7 D063646
650    _2
$a buněčná diferenciace $7 D002454
650    _2
$a kolagenasy $x škodlivé účinky $7 D017364
650    _2
$a extracelulární matrix $x metabolismus $7 D005109
650    _2
$a lidé $7 D006801
650    12
$a transplantace mezenchymálních kmenových buněk $x škodlivé účinky $7 D045164
650    _2
$a mezenchymální kmenové buňky $x cytologie $7 D059630
650    _2
$a fyziologická neovaskularizace $7 D018919
650    _2
$a osteogeneze $7 D010012
650    _2
$a pluripotentní kmenové buňky $x transplantace $7 D039904
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a poranění šlachy $x chemicky indukované $x patologie $x patofyziologie $x chirurgie $7 D013708
650    12
$a hojení ran $7 D014945
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sedlacek, Radek
700    1_
$a Suchy, Tomas
700    1_
$a Amemori, Takashi $7 gn_A_00005511
700    1_
$a Ruzicka, Jiri
700    1_
$a Lesny, Petr
700    1_
$a Havlas, Vojtech
700    1_
$a Sykova, Eva
700    1_
$a Jendelova, Pavla
773    0_
$w MED00008166 $t Biomedical engineering online $x 1475-925X $g Roč. 13, č. - (2014), s. 42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24712305 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141007111914 $b ABA008
999    __
$a ok $b bmc $g 1042123 $s 873152
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 13 $c - $d 42 $i 1475-925X $m Biomedical engineering online $n Biomed Eng Online $x MED00008166
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...